The principles of treatment for allergic rhinitis are environmental control, medication, immunotherapy and health education. In cases where complete allergen avoidance is not possible, medications are needed to control symptoms and immunotherapy to modify the disease process. Pharmacological treatment of allergic rhinitis includes mainly nasal glucocorticoids, oral or nasal antihistamines, white triplet receptor antagonists, and decongestants. Immunotherapy includes subcutaneous injections and sublingual therapy. For children, pregnant women and the elderly, the three groups of people with allergic rhinitis, how to use medication safely and effectively is the focus of attention. For children, nasal glucocorticoid sprays can reduce nasal allergy symptoms while effectively treating intranasal congestion, and mometasone furoate can be used in children over 2 years of age. Oral or nasal antihistamines are available, including cetirizine for children over 6 months of age, loratadine for children over 2 years of age, and nasal sprays for children over 6 years of age. The leukotriene receptor antagonist montelukast sodium is effective in improving nasal congestion and runny symptoms and is used in children over 2 years of age. Decongestants of the nasal mucosa are not recommended for use in children. Nasal irrigation is a simple and effective treatment that can be used in children. For children over 3 years of age, sublingual immunotherapy is an option, and subcutaneous immunotherapy can be used for children over 5 years of age. In pregnant women, the effect of increased circulating blood volume and hormone secretion in the nasal mucosa during pregnancy can lead not only to hormonal rhinitis during pregnancy, but also to aggravation of existing allergic rhinitis symptoms, especially nasal congestion. Nasal glucocorticoids can reach high concentrations in the nasal mucosa and have low bioavailability, reducing the risk of systemic adverse effects and possible effects on the fetus, and no adverse events have been observed with clinical use of budesonide. Second-generation antihistamines cetirizine and loratadine can be chosen, but try not to use them in the first trimester of pregnancy, and try to avoid fexofenadine and azulfidine drugs. It is recommended that nasal glucocorticoids and nasal antihistamines can be used together. The leukotriene receptor antagonist montelukast can be used, but be aware of its adverse effects. The use of nasal mucosal decongestants during pregnancy is not recommended. Hypertonic saline rinses of the nasal cavity are recommended. For immunotherapy, if started before pregnancy, immunotherapy may be continued during pregnancy if there are no adverse effects; starting immunotherapy during pregnancy is not recommended. In the elderly, due to the presence of multiple medications, drug-drug interactions should be considered, as well as adherence. Nasal glucocorticoids can be chosen from mometasone furoate and fluticasone propionate, but be aware of their side effects, including nasal dryness, nasal mucosal burning, nasal crusting and rhinorrhea. Oral second-generation antihistamines can be chosen, as well as nasal antihistamines to reduce the systemic side effects of oral administration. Leukotriene receptor antagonists are used to treat mild and moderate/severe allergic rhinitis and are particularly effective in improving nasal congestion symptoms and sleep quality. Nasal mucosal decongestants are not indicated in the elderly, especially in patients with cardiovascular disease, bladder neck obstruction and vascular cognitive impairment. Physiological saline can be used to rinse the nasal passages. Immunotherapy has the same efficacy and safety profile for the elderly as it does for younger patients and is an option after risk assessment.